CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,370 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00883181
NCT00883181N/ACompleted
CompareCT.gov

A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy

Amgen·observational·Posted Apr 17, 2009·Updated Mar 15, 2017

In Brief

An observational study for Breast Cancer and 3 related conditions. Completed, enrolled 1,370 participants.

Detailed Summary

The primary objective was to describe the incidence of febrile neutropenia based on granulocyte-colony stimulating factor (G-CSF) use (primary, secondary, treatment, or no usage) in patients receiving myelotoxic chemotherapy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Small Cell Lung Cancer
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 17, 2009
Enrollment StartNov 1, 2006
Primary CompletionOct 1, 2009
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.2 years ago